# Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

> **NCT05175625** · PHASE3 · COMPLETED · sponsor: **Cinnagen** · enrollment: 300 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- **BIOLOGICAL:** Saline placebo

## Key facts

- **NCT ID:** NCT05175625
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-06-20
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2022-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05175625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05175625, "Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05175625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*